Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 14/20 | 0.45 |
| ▸ | TYK2 | P29597 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29739879 | 0.83 | CYP19A1 (0.42) | CYP19A1CA2KMT2A | |
| SCHEMBL20073552 | 0.83 | CYP19A1 (0.42) | CYP19A1CA2KMT2A | |
| SCHEMBL20225772 | 0.77 | CYP19A1 (0.51) | CYP19A1TYK2 | |
| SCHEMBL23933005 | 0.76 | ALDH1A1 (0.44) | CYP19A1CA2LMNAKMT2APTGS2 | |
| SCHEMBL29686091 | 0.76 | ALDH1A1 (0.44) | CYP19A1CA2LMNAKMT2APTGS2 | |
| SCHEMBL25213378 | 0.75 | CA1 (0.44) | CYP19A1CA2 | |
| SCHEMBL20073375 | 0.74 | TDP1 (0.43) | CYP19A1TYK2CA2LMNATP53 | |
| SCHEMBL29686578 | 0.74 | TDP1 (0.43) | CYP19A1TYK2CA2LMNATP53 | |
| SCHEMBL24498465 | 0.73 | KMT2A (0.47) | CYP19A1CA2LMNATP53KMT2A | |
| SCHEMBL29686620 | 0.73 | KMT2A (0.47) | CYP19A1CA2LMNATP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210230163-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-07-29 | — | — | US | disclosed |
| EP-3848370-A2 | TYK2 INHIBITORS AND USES THEREOF | Nimbus Lakshmi, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | US | disclosed |
| US-10793574-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190284194-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-19 | — | — | US | disclosed |
| US-10323036-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
| WO-2018075937-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| WO-2018071794-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CYP19A1 2724/4885TYK2 1/4885CA2 4600/4885 |
| US-10793574-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | CYP19A1 2724/4885TYK2 1/4885CA2 4600/4885 |
| US-10323036-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | CYP19A1 2724/4885TYK2 1/4885CA2 4600/4885 |
| US-20210230163-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CYP19A1 2724/4885TYK2 1/4885CA2 4600/4885 |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CYP19A1 2724/4885TYK2 1/4885CA2 4600/4885 |
| US-20190284194-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CYP19A1 2724/4885TYK2 1/4885CA2 4600/4885 |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CYP19A1 2724/4885TYK2 1/4885CA2 4600/4885 |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | CYP19A1 2724/4885TYK2 1/4885CA2 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.